How to buy Viking Therapeutics (VKTX) shares in Australia
Learn how to easily invest in Viking Therapeutics shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Viking Therapeutics Inc is a biotechnology business with stocks listed in the US. Viking Therapeutics shares (VKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$5.76 – a decrease of 4.16% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Viking Therapeutics
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Viking Therapeutics. Find the share by name or ticker symbol: VKTX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Viking Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$7.04, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Viking Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Viking Therapeutics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Viking Therapeutics key stats
- Compare share trading platforms
- Is Viking Therapeutics stock a buy or sell?
- Viking Therapeutics performance over time
- Can I short Viking Therapeutics shares?
- Viking Therapeutics's financials
- How volatile are Viking Therapeutics shares?
- Does Viking Therapeutics pay a dividend?
- Other common questions
Viking Therapeutics stock price (NASDAQ:VKTX)Use our graph to track the performance of VKTX stocks over time.
Viking Therapeutics shares at a glance
|52-week range||US$5.12 - US$10.09|
|50-day moving average||US$6.3146|
|200-day moving average||US$6.0498|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$-0.666|
Where to buy Viking Therapeutics stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Viking Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying Viking Therapeutics shares?Before you consider Viking Therapeutics, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
Viking Therapeutics price performance over time
|1 week (2021-10-14)||-6.34%|
|1 month (2021-09-24)||-11.11%|
|3 months (2021-07-23)||-0.17%|
|6 months (2021-04-23)||-4.32%|
|1 year (2020-10-23)||0.70%|
|2 years (2019-10-24)||-10.84%|
|3 years (2018-10-24)||-53.55%|
|5 years (2016-10-24)||443.40%|
Stocks similar to Viking Therapeutics
Viking Therapeutics financials
|Gross profit TTM||US$0|
|Return on assets TTM||-12.49%|
|Return on equity TTM||-20.38%|
|Market capitalisation||US$450.4 million|
TTM: trailing 12 months
Shorting Viking Therapeutics shares
There are currently 5.1 million Viking Therapeutics shares held short by investors – that's known as Viking Therapeutics's "short interest". This figure is 13.4% down from 5.9 million last month.
There are a few different ways that this level of interest in shorting Viking Therapeutics shares can be evaluated.
Viking Therapeutics's "short interest ratio" (SIR)
Viking Therapeutics's "short interest ratio" (SIR) is the quantity of Viking Therapeutics shares currently shorted divided by the average quantity of Viking Therapeutics shares traded daily (recently around 695147.39726027). Viking Therapeutics's SIR currently stands at 7.3. In other words for every 100,000 Viking Therapeutics shares traded daily on the market, roughly 7300 shares are currently held short.
However Viking Therapeutics's short interest can also be evaluated against the total number of Viking Therapeutics shares, or, against the total number of tradable Viking Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viking Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Viking Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0763% of the tradable shares (for every 100,000 tradable Viking Therapeutics shares, roughly 76 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Viking Therapeutics.
Find out more about how you can short Viking Therapeutics stock.
Viking Therapeutics share dividends
We're not expecting Viking Therapeutics to pay a dividend over the next 12 months.
Viking Therapeutics share price volatility
Over the last 12 months, Viking Therapeutics's shares have ranged in value from as little as US$5.12 up to US$10.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viking Therapeutics's is 1.8175. This would suggest that Viking Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Viking Therapeutics overview
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Viking Therapeutics in the news
10 Healthcare Stocks to Buy According to Peter S. Park’s Park West Asset Management
Viking Therapeutics to Present at H.C. Wainwright's 5th Annual NASH Investor Conference
Viking Therapeutics : to Present at H.C. Wainwright's 5th Annual NASH Investor Conference
Frequently asked questions
More guides on Finder
How to buy BITO ETF units | $39.51
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Why is the AMP share price looking up today?
Shares in the wealth management giant have been largely stable in the last 6 months.
How to invest in the Judo Capital Holdings IPO
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
How to invest in the Alloggio Group IPO
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
How to invest in the Larvotto Resources IPO
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
How to invest in the Vulcan Steel IPO
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
How to invest in the Artrya IPO
Everything we know about the Artrya IPO, plus information on how to buy in.
How to invest in the 8 Au IPO
Everything we know about the 8 Au IPO, plus information on how to buy in.
How to invest in the Radiopharm Theranostics IPO
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
What has prompted the rebound in the Kogan share price?
The online retailer’s shares have lost more than half their value in the last 12 months.
Ask an Expert